MannKind Corporation
MNKD
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
MannKind Corporation is a pharmaceutical company whose primary product, Afrezza, is an inhaled insulin. The development and regulatory approval of Afrezza involved animal testing. As a biotechnology firm engaged in drug development, MannKind's business model inherently relies on animal research for preclinical safety and efficacy studies, a standard industry practice for gaining FDA approval of new drug applications. The company's public filings and regulatory correspondence do not disclose a commitment to alternative testing methods or a policy against animal testing for its product pipeline.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.